William Richard White Sells 139,083 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO William Richard White sold 139,083 shares of the firm’s stock in a transaction that occurred on Wednesday, July 24th. The shares were sold at an average price of $26.98, for a total transaction of $3,752,459.34. Following the sale, the chief financial officer now directly owns 41,791 shares of the company’s stock, valued at approximately $1,127,521.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

William Richard White also recently made the following trade(s):

• On Tuesday, July 16th, William Richard White sold 34,811 shares of Akero Therapeutics stock. The stock was sold at an average price of $28.04, for a total transaction of $976,100.44.
• On Tuesday, June 11th, William Richard White sold 2,831 shares of Akero Therapeutics stock. The stock was sold at an average price of $22.64, for a total transaction of $64,093.84.

Akero Therapeutics Stock Performance

AKRO stock traded up $1.50 during mid-day trading on Thursday, hitting $28.32. The company had a trading volume of 647,035 shares, compared to its average volume of 1,059,874. The company has a 50-day moving average price of $22.66 and a 200 day moving average price of $22.93. The company has a quick ratio of 30.12, a current ratio of 30.12 and a debt-to-equity ratio of 0.04. Akero Therapeutics, Inc. has a 12-month low of $11.25 and a 12-month high of $53.77.

Akero Therapeutics (NASDAQ:AKRO) last announced its earnings results on Friday, May 10th. The company reported ($0.90) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.90). On average, research analysts predict that Akero Therapeutics, Inc. will post -3.82 EPS for the current year.

Institutional Trading of Akero Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC raised its position in Akero Therapeutics by 42.2% in the 1st quarter. Janus Henderson Group PLC now owns 6,121,970 shares of the company’s stock worth $154,589,000 after purchasing an additional 1,815,569 shares during the period. Price T Rowe Associates Inc. MD raised its position in Akero Therapeutics by 10.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,060,479 shares of the company’s stock worth $102,569,000 after purchasing an additional 384,555 shares during the period. Vanguard Group Inc. raised its position in Akero Therapeutics by 19.0% in the 1st quarter. Vanguard Group Inc. now owns 3,669,923 shares of the company’s stock worth $92,702,000 after purchasing an additional 584,875 shares during the period. RTW Investments LP purchased a new stake in Akero Therapeutics in the 4th quarter worth about $83,891,000. Finally, Wellington Management Group LLP raised its position in Akero Therapeutics by 247.7% in the 4th quarter. Wellington Management Group LLP now owns 2,881,989 shares of the company’s stock worth $67,294,000 after purchasing an additional 2,053,028 shares during the period.

Analyst Ratings Changes

A number of research analysts recently weighed in on AKRO shares. Bank of America started coverage on shares of Akero Therapeutics in a research note on Monday, April 22nd. They set a “neutral” rating and a $30.00 target price on the stock. Canaccord Genuity Group lowered their target price on shares of Akero Therapeutics from $59.00 to $56.00 and set a “buy” rating on the stock in a research note on Monday, May 13th. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Akero Therapeutics in a research note on Tuesday, June 11th. Wolfe Research started coverage on shares of Akero Therapeutics in a report on Tuesday, June 11th. They issued an “outperform” rating on the stock. Finally, Evercore ISI decreased their price target on shares of Akero Therapeutics from $50.00 to $38.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 15th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $41.13.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.